Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    November 2023
  1. WANG Y, Wen J, Sun X, Sun Y, et al
    CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
    Cancer Chemother Pharmacol. 2023 Nov 8. doi: 10.1007/s00280-023-04610.
    >> Share

    August 2023
  2. NWABUFO CK
    Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
    Cancer Chemother Pharmacol. 2023 Aug 18. doi: 10.1007/s00280-023-04575.
    >> Share

    June 2023
  3. KONIG P, Zhulenko R, Suparman E, Hoffmeister H, et al
    A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
    Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04548.
    >> Share

  4. HONG L, Wang X, Zheng L, Wang S, et al
    Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
    Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04533.
    >> Share

  5. HU C, Zhang Y, Pei T, Liu P, et al
    Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Cancer Chemother Pharmacol. 2023;91:523-529.
    >> Share

    March 2023
  6. BAUM J, Zickler D, Bolbrinker J, Richter R, et al
    Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.
    Cancer Chemother Pharmacol. 2023 Mar 22. doi: 10.1007/s00280-023-04514.
    >> Share

  7. DE JONG LAW, Lambert M, van Erp NP, de Vries L, et al
    Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
    Cancer Chemother Pharmacol. 2023 Mar 9. doi: 10.1007/s00280-023-04512.
    >> Share

    May 2022
  8. MASSAI L, Messori L, Carpentieri A, Amoresano A, et al
    The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study.
    Cancer Chemother Pharmacol. 2022 May 11. pii: 10.1007/s00280-022-04438.
    >> Share

    April 2022
  9. MANZO J, Puhalla S, Pahuja S, Ding F, et al
    A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2022 Apr 18. pii: 10.1007/s00280-022-04430.
    >> Share

  10. XU J, Gao Y, Luan X, Li K, et al
    An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Cancer Chemother Pharmacol. 2022 Apr 13. pii: 10.1007/s00280-022-04403.
    >> Share

  11. GREEN ML, Ma SC, Goble S, Giordano H, et al
    Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
    Cancer Chemother Pharmacol. 2022 Apr 10. pii: 10.1007/s00280-022-04413.
    >> Share

    October 2021
  12. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    >> Share

    July 2021
  13. SUGISAWA N, Higuchi T, Han Q, Hozumi C, et al
    Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Cancer Chemother Pharmacol. 2021;88:61-67.
    >> Share

    June 2021
  14. SOKOLENKO AP, Gorodnova TV, Bizin IV, Kuligina ES, et al
    Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 2. pii: 10.1007/s00280-021-04301.
    >> Share

    April 2021
  15. VAULEON E, Behal H, Lebellec L, Desbarbieux R, et al
    Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
    Cancer Chemother Pharmacol. 2021;87:533-541.
    >> Share

    January 2021
  16. LIU YK, Jia YJ, Liu SH, Ma J, et al
    FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-kappaB pathway.
    Cancer Chemother Pharmacol. 2021 Jan 3. pii: 10.1007/s00280-020-04215.
    >> Share

    October 2020
  17. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016